Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Orphan rules finally in place

OXFORD - The European Commission last week adopted rules for obtaining orphan drug designation, allowing companies to apply to the European Agency for the Evaluation of Medicinal Products (EMEA) to designate their candidate medicines as "orphan medicinal products" for patients with diseases that affect fewer than 5 patients in every 10,000 of the population in the European Union. Successful orphan drugs could receive up to 10 years of market exclusivity in the EU.

The rule implements European

Read the full 767 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE